SCR-M015 / Simcere - LARVOL DELTA

SCR-M015, a PD-1/VEGF bispecific antibody exhibits potent anti-tumor efficacy in preclinical studies (AACR 2026) - "SCR-M015 inhibits PD-1/PD-L1 signaling and VEGF-A/VEGFR2 signaling in vitro and shows potent and superior anti-tumor activity in vivo. These preclinical data demonstrates the promising potential for further clinical investigation in various types of tumors."

Bispecific • Preclinical • Oncology • IFNG • IL2 • PD-1